FDA Granted Fast Track Status for Cancer Drug TRE-515

The drug targets G12C mutation-positive non-small cell lung cancer for patients who have exhausted other options.

Updated on Oct. 1, 2026 in Cancer

FDA Granted Fast Track Status for Cancer Drug TRE-515

Live Poll

Should the government expedite the regulatory approval process for experimental cancer drug combinations?

The U.S. Food and Drug Administration has granted Fast Track designation to the oral drug TRE-515. The treatment is intended for patients with G12C mutation-positive non-small cell lung cancer who have previously received anti-PD-(L)1 antibody and platinum-based chemotherapy.

Why it matters

Tumors may rely on the nucleoside salvage pathway for metabolic support when subjected to therapeutic stress from KRAS inhibitors. By inhibiting the enzyme deoxycytidine kinase, TRE-515 aims to improve clinical outcomes for patients in this population.

This marks the second FDA Fast Track designation for TRE-515, which functions as an oral capsule. Trethera Corporation, the developer, was also awarded a $2.7 million NIH grant in 2025.

The players

Trethera Corporation

Based in Los Angeles, this biotechnology firm focuses on developing therapies that target the metabolic vulnerabilities of cancer cells.

Food and Drug Administration

This federal agency is responsible for protecting public health by ensuring the safety, efficacy, and security of human drugs and biological products in the United States.

The details

TRE-515 works by blocking deoxycytidine kinase activity within the nucleoside salvage pathway. It is designed to be used in combination with KRAS inhibitors to address advanced stages of non-small cell lung cancer.

Trethera Corporation received a $2.7 million NIH grant in 2025.
The FDA granted Fast Track designation for TRE-515 on October 01, 2026.

Cancer
Sept. 29
AstraZeneca Filed for Lung Cancer Drug Approval
Cancer
Sept. 21
FDA Conditionally Accepted Name for Lirafugratinib
Cancer
Sept. 28
NeOnc Will Meet With FDA on November 17, 2026

The Big Picture

The granting of this status follows the established regulatory framework of the FDA Fast Track program. This designation provides a mechanism to speed up the development of therapies for serious conditions through increased communication and priority review.

This designation potentially shortens the time required for a promising treatment to reach the market for patients with limited options. Patients should consult with their oncologists to understand how emerging targeted therapies may fit into their current treatment plans.

The takeaway

Fast Track status facilitates more frequent engagement with regulators to help move specialized cancer treatments through the approval pipeline. Patients and providers should monitor for upcoming clinical trial results that will define the practical application of this therapy.